221 related articles for article (PubMed ID: 31312209)
21. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
[TBL] [Abstract][Full Text] [Related]
22. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
[TBL] [Abstract][Full Text] [Related]
23. Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients.
Niedrig DF; Rahmany A; Heib K; Hatz KD; Ludin K; Burden AM; Béchir M; Serra A; Russmann S
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361984
[TBL] [Abstract][Full Text] [Related]
24. Clinical Application of Pharmacogenetics: Where are We Now?
van Schaik RH;
EJIFCC; 2013 Feb; 24(3):105-12. PubMed ID: 27683445
[TBL] [Abstract][Full Text] [Related]
25. Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands.
Bank PCD; Swen JJ; Guchelaar HJ
BMC Med; 2019 Jun; 17(1):110. PubMed ID: 31196067
[TBL] [Abstract][Full Text] [Related]
26. Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM; Schneider T; Meienberg J; Matyas G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225115
[TBL] [Abstract][Full Text] [Related]
27. Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey ET; Ragan AK; Oyen LJ; Vitek CR; Aoudia SL; Ragab AK; Fee-Schroeder KC; Black JL; Moyer AM; Nicholson WT; Shrestha S; McAllister TM; Sinnwell JP; Faubion SS; Lazaridis KN
Pharmacogenomics J; 2022 Feb; 22(1):69-74. PubMed ID: 34671112
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China.
Huang Q; Liao Y; Yu T; Lei W; Liang H; Wen J; Liu Q; Chen Y; Huang K; Jing L; Huang X; Liu Y; Yu X; Su K; Liu T; Yang L; Huang M
J Clin Lab Anal; 2023 Mar; 37(5):e24855. PubMed ID: 36916827
[TBL] [Abstract][Full Text] [Related]
29. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
30. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
[TBL] [Abstract][Full Text] [Related]
31. Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer.
Bernard PS; Wooderchak-Donahue W; Wei M; Bray SM; Wood KC; Parikh B; McMillin GA
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799547
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
33. Computational pharmacogenotype extraction from clinical next-generation sequencing.
Shugg T; Ly RC; Osei W; Rowe EJ; Granfield CA; Lynnes TC; Medeiros EB; Hodge JC; Breman AM; Schneider BP; Sahinalp SC; Numanagić I; Salisbury BA; Bray SM; Ratcliff R; Skaar TC
Front Oncol; 2023; 13():1199741. PubMed ID: 37469403
[TBL] [Abstract][Full Text] [Related]
34. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
[TBL] [Abstract][Full Text] [Related]
35. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.
Pratt VM; Cavallari LH; Del Tredici AL; Gaedigk A; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; van Schaik RHN; Whirl-Carrillo M; Weck KE
J Mol Diagn; 2021 Sep; 23(9):1047-1064. PubMed ID: 34118403
[TBL] [Abstract][Full Text] [Related]
36. A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.
Bank PCD; Swen JJ; Schaap RD; Klootwijk DB; Baak-Pablo R; Guchelaar HJ
Eur J Hum Genet; 2019 Oct; 27(10):1532-1541. PubMed ID: 31227807
[TBL] [Abstract][Full Text] [Related]
37. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Zhu Y; Moriarty JP; Swanson KM; Takahashi PY; Bielinski SJ; Weinshilboum R; Wang L; Borah BJ
Genet Med; 2021 Mar; 23(3):461-470. PubMed ID: 33041335
[TBL] [Abstract][Full Text] [Related]
38. Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization.
Westergaard N; Baltzer Houlind M; Christrup LL; Juul-Larsen HG; Strandhave C; Olesen AE
Basic Clin Pharmacol Toxicol; 2024 Apr; 134(4):531-542. PubMed ID: 38308569
[TBL] [Abstract][Full Text] [Related]
39. A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources.
Palumbo S; Mariotti V; Pellegrini S
J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):49-56. PubMed ID: 38100778
[TBL] [Abstract][Full Text] [Related]
40. Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.
Chhibber A; Watanabe AH; Jacobs H; Kharat A; Syeed SM; Sherwin CM; Chaiyakunapruk N; Biskupiak J; Yellepeddi VK; Brixner D; Young DC
J Cyst Fibros; 2024 Jun; ():. PubMed ID: 38937211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
